Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...

Key Takeaways Merck shares fell sharply Tuesday morning after the drugmaker's profits and 2025 outlook fell short of ...

Merck’s stock tumbled 6% early Tuesday, after the drug company’s softer-than-expected guidance for the current year offset ...

Vamil Divan, Guggenheim Securities biopharmaceutical analyst, joins 'Power Lunch' to discuss Merck's troubles in China.

Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...

Merck (MRK) stock sank like a stone on Tuesday after the pharmaceutical giant posted poor guidance for the rest of the year.

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

Gardasil shipment pause, weak guidance, and looming Keytruda risks send investors scrambling--can Merck turn things around?

Merck ( MRK) reported fourth quarter and full year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the ...

While reporting financial results for the fourth quarter on Tuesday, biopharmaceutical company Merck & Co., Inc. (MRK), known as MSD ...

Stocks are struggling for direction today, and one sector that represents this choppiness is blue-chip drugmakers. Merck & Co ...